Aripiprazole
Product Images NDC 68151-4459

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68151-4459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (68151 4459)

Aripiprazole 10 mg tablet label showing product name, strength, lot number, expiration date, quantity of 16 tablets, and labeling by Carilion Materials Management. The label includes NDC and prescription-only designation (Rx only).*

FDA Label Image

Figure 3 (Aripiprazole 3figure)

A forest plot chart displaying fold change and 90% confidence intervals for various drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, desmethylvenlafaxine, and escitalopram. The x-axis represents change relative to a reference without interacting drug, ranging from 0.5 to 3, with data points for AUC and Cmax values shown as black squares with horizontal error bars.*

FDA Label Image

Figure 1 (Aripiprazole Figure1)

A horizontal bar chart titled 'Effect of Other Drugs on Aripiprazole' illustrating the fold change and 90% confidence intervals for AUC and Cmax of Aripiprazole when co-administered with various drugs, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam). The x-axis shows change relative to reference from 0.5 to 3.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

A pharmacokinetic effect chart illustrating the impact of various drugs on Aripiprazole and its metabolite Dehydro-Aripiprazole. The chart shows fold change with 90% confidence intervals for AUC and Cmax relative to a reference without interacting drugs, categorized by CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

A chart titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic parameters AUC and Cmax comparing special populations relative to a reference. Categories include CYP2D6 metabolizer status, gender, age groups, and levels of hepatic and renal impairment. The chart plots changes in these parameters with confidence intervals across these groups.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

A chart comparing fold change and 90% confidence intervals for Dehydro-Aripiprazole pharmacokinetics. Variables include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, shown as changes in AUC and Cmax relative to reference.*

FDA Label Image

Figure 6 (Aripiprazole Figure6)

A line graph comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The number of subjects at risk is noted below the x-axis for both groups at multiple time points.*

FDA Label Image

Structure (Aripiprazole Str)

Chemical structure of aripiprazole showing its atomic arrangement and connectivity, including two chlorine substituents, a piperazine ring, and a fused bicyclic system with an oxygen-containing functional group.*

FDA Label Image

Trigen Laboratories Llc (Aripiprazole Trigen)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.